GlaxoSmithKline, which was fined $483 million for corruption in China last year and is examining possible staff misconduct elsewhere, faces new allegations of bribery in Romania.

The company already is probing alleged bribery in Poland, the United Arab Emirates, Lebanon, Jordan, Syria and Iraq.